OncoMatch/Clinical Trials/NCT05305131
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
Is NCT05305131 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including cisplatin and gemcitabine and induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab. for nasopharyngeal cancer.
Treatment: cisplatin and gemcitabine · induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab. — The investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabine in patients with locally advanced nasopharyngeal cancer (NPC)
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV EBV-encoded small RNA positive by EBER in situ hybridization
locally or centrally determined EBV-positive NPC by EBV-encoded small RNA in situ hybridization (EBER in situ hybridization [ISH]) assay
Disease stage
Required: Stage III, IVA (AJCC 8th edition)
Excluded: Stage III T3N0, III T3N1
Tumour stage III (except for T3N0 and T3N1) or IVA according to the American Joint Committee on Cancer (AJCC) 8th edition criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify